Antibiotics help treat depression, anxiety, migraines in India

ANI: Antibiotics have been used to treat a range of conditions for centuries, including depression, as well as anxiety and migrainous pain.

Now a new study by India’s Institute of Pharmaceutical Sciences has found that they can also be used to help people feel happier and happier.

Antidepressants are a group of drugs that are meant to ease the symptoms of depression.

When taken as prescribed, they can help treat anxiety and help people overcome stress.

But there is some controversy around how well they work.

The drug metoclopramide (MMP) is one of the most widely prescribed antidepressant drugs in the world.

It is prescribed to treat major depressive disorder (MDD) in about a quarter of the US population.

But it is not approved for treating major depression in India.

Its use is restricted to a small group of patients who are treated with a drug that treats a much broader range of illnesses, including obesity, heart disease and cancer.

MMP was originally developed in the 1950s by the US pharmaceutical company Pfizer.

It was approved in the US for the treatment of anxiety disorders in 1997.

But it was not approved in India until 2005, when the government banned the drug from being used for any other medical purpose.

India’s government then asked the pharmaceutical industry to stop using MMP for depression.

But the industry refused to do so.

Since then, India has been working with the industry to get it approved in other countries.

In 2016, India became the first country to grant a patent to a new class of antidepressant called mocloprid-5.

This is a class of drugs developed by the UK-based drug company Gilead Sciences.

Its drugs are known as selective serotonin reuptake inhibitors (SSRI), or SSRIs.

Their side effects include depression, insomnia and nausea.

According to the US Drug Enforcement Administration, there are about 2.5 million prescriptions for SSRI in the United States.

India is the second largest market for the drugs in India, after China.